Introduction
It is nearly 25 
Safety
It is impossible to claim safety for any drug until it has been in use for a number of years. Thus, several years elapsed before the toxicity of chloramphenicol was apparent.
One of the derivatives of erythromycin used, i.e. erythromycin estolate, has itself been found to be hepato-toxic. Thus, some patients who received this drug for more than 2 weeks were found to suffer from liver damage and sometimes developed frank jaundice, although most recovered when the drug was stopped. This toxicity contrasts with the lack of toxicity of erythromycin base itself. Thus it has been stated recently 'no toxic effects of any consequence have ever been recorded from the administration of erythromycin base' and 'there is no doubt that erythromycin is one of the most innocuous antibiotics in current use' (Garrod, Lambert and O'Grady, 1973 (Lacey, 1973) . The idea that bacteria mutate to erythromycin resistance and that mutation is encouraged by prolonged use of the drug is probably erroneous (Lacey, 1976) .
Effect on normal bacterial flora
The ideal antibiotic is one that destroys the infecting organism and offers no toxicity to the host. We have discussed already the lack of side effects associated with the use of erythromycin when considering its direct effect upon the human body. Many antibiotics produce side effects indirectlyby eliminating some of the normal flora, particularly those in the gut. Well known examples of these include tetracycline, ampicillin and oral neomycin. Severe gastro-intestinal side effects have virtually never been reported following the use of erythromycin.
When considering the long term use of erythromycin, another important aspect is its effect on the gut flora. This is the unlikelihood of its use promoting the appearance of strains of Escherichia coli resistant to other antibiotics (Gould, 1975 In the latter instance, a throat swab is mandatory. Another reason for not prescribing a penicillin routinely for trivial infections is that the widespread use of this antibiotic will select strains of many bacterial species that are resistant to penicillin and ampicillin (Manners et al., 1976 One of the factors in selecting a drug for prostatitis will be the degree of penetration of the antibiotic into the prostatic fluid. This is usually assessed by the presence of the antibiotic in seminal fluid in man (e.g. Malmborg, et al., 1976) or in prostatic fluid from experimental animals.
Previously, tetracycline has been advocated as the drug of choice in treating prostatitis. Certainly penicillin or ampicillin are not generally recommended because the microbes that are thought to be a cause of prostatitis do not have conventional bacterial cell walls on which penicillin acts; in other words, the bacteria are resistant.
Alternative drugs include erythromycin and injectable antibiotics which act on protein synthesis rather than the cell wall. However, data showing whether tetracycline is superior to erythromycin are scanty and either drug would seem to be a very reasonable choice in the treatment of this condition.
Mycoplasma
Mycoplasma infections occur in two main sites in man:
(1) Primary atypical pneumonia.
(2) Genital infections.
There is a growing body of opinion that implicates Mycoplasma infection in abortion and/or sterility in the female, and non-specific (non-gonococcal) urethritis in the male.
However, it must be stated that some of the evidence on which this opinion is based is inconclusive. In the treatment of Mycoplasma infections, (Lacey and Lewis, 1976) and it would now seem unwise to rely on flucloxacillin alone in treating osteomyelitis. A similar argument applies to the cephalosporins where some, such as cephaloridine, are highly inactivated by the penicillinase and there is experimental and therapeutic evidence that supports this (Burgess and Evans, 1966) . Other agents that have been used in the treatment of osteomyelitis include fusidic acid, erythromycin and lincomycin. There would seem to be no advantage of lincomycin over erythromycin and indeed there is good clinical evidence that combinations of erythromycin and fusidic acid produce good therapeutic effect in osteomyelitis (Blockey and McAllister, 1972) .
